Gallincin ameliorates colitis-associated inflammation and barrier function in mice based on network pharmacology prediction

De-jun Cui¹,²,³,* , Xiao-lan Yang²,* , Shujiro Okuda³, Yi-wei Ling³, Zhu-xue Zhang⁴, Qi Liu², Wen-qiang Yuan¹,² and Fang Yan¹,²

Abstract

Objective: To explore potential mechanisms and effects of gallincin on a mouse model of colitis induced by dextran sulfate sodium (DSS).

Methods: Network pharmacology analysis was used to predict the molecular mechanism of action of gallincin for treatment of colitis. Gallincin was administered orally to mice with DSS-induced colitis. Expression of tumor necrosis factor α (TNF-α), D-lactate, and interleukin-1β (IL-1β) and myeloperoxidase activity were assessed with real-time quantitative PCR and an enzyme-linked immunoassay, respectively. Expression of occludin, zonula occludens 1 (ZO-1), and phosphorylated extracellular signal-regulated protein kinase1/2 (p-ERK1/2) was analyzed with immunohistochemical staining and/or western blot assays.

Results: Using a network pharmacology approach, 12 mapping targets between gallincin and colitis were obtained, including ERK/mitogen-activated protein kinase. Further investigations in an experimental colitis mouse model showed that gallincin significantly ameliorated experimental colitis, reduced D-lactate levels, and remarkably increased occludin and ZO-1 expression, possibly in part by decreasing IL-1β, TNF-α, and p-ERK1/2 levels and inhibiting leukocyte penetration.

Conclusions: Gallincin regulated colonic barrier function and reduced colitis-associated inflammation, suggesting it is a promising drug for the treatment of ulcerative colitis.

¹Department of Gastroenterology, Guizhou Provincial People’s Hospital, Guiyang, China
²Guizhou Medical University, Guiyang, China
³Division of Bioinformatics, Niigata University Graduate School of Medical and Dental Sciences, Japan
⁴Pathology, Guizhou Provincial People’s Hospital, Guiyang, China

*These authors contributed equally to this paper.

Corresponding author:
De-jun Cui, Department of Gastroenterology, Guizhou Provincial People’s Hospital, No. 83, East Zhongshan Road, Guiyang, Guizhou Province 550002, China.
Email: hxcuidj@163.com

Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
Keywords
Gallincin, network pharmacology, ulcerative colitis, inflammation, tight junction proteins, dextran sodium sulfate

Date received: 27 March 2020; accepted: 28 July 2020

Introduction
Ulcerative colitis (UC), the most common type of human inflammatory bowel disease (IBD), is a refractory idiopathic disease that mainly affects the colorectal area.1 Although the definitive etiology of UC remains unclear, numerous studies suggest that impaired colorectal barrier function plays a significant role in the pathogenesis of UC.2,3 In fact, previous studies have implicated proinflammatory cytokines in epithelial barrier dysfunction, which in turn enhances antigenic exposure to underlying immune cells.4,5 Therefore, blocking the vicious chain reaction of intestinal barrier dysfunction and excessive inflammation is of important clinical significance for UC.

Currently, approved drugs for UC mainly include chronic administration of 5-aminosalicylic acid drugs, glucocorticosteroids, immunosuppressants, and anti-tumor necrosis factor α (TNF-α) monoclonal antibodies.1,6 However, these conventional therapies produce variable response rates and are not always advisable as a maintenance therapy because of a variety of systemic adverse reactions and high cost.7,8 Interestingly, traditional Chinese medicine may be a promising complementary treatment for UC.7,9,10 Gallincin (methyl 3,4,5-trihydroxybenzoate), which is extracted from plants, has significant biological properties. Previous studies have shown that gallincin elicits anti-inflammatory effects by inhibiting activation of extracellular-signal regulated protein kinase (ERK).11 In addition, gallincin has spasmolytic, anti-inflammatory, antidiarrheal, and antioxidant actions.12,13 However, it is still unknown whether intestinal barrier dysfunction can be treated by gallincin. Fortunately, network pharmacology can be used to identify potential mechanisms of traditional Chinese medicine.14,15 Thus, based on network pharmacology, this study was designed to explore whether gallincin protects against experimental UC by inhibiting inflammation and mucosal damage.

Methods

Prediction of targets of gallincin
First, we obtained the simplified molecular input line entry system (SMILES) data for gallincin from the PubChem database. Next, targets of gallincin were predicted using the Swiss Target Prediction Database (http://www.swisstargetprediction.ch/) and Binding Database (http://www.bindingdb.org/bind/index.jsp).16,17 The query keywords were “gallincin” and its synonyms. Homo sapiens was selected in the Swiss Target Prediction Database. Substructure and similarity (≥0.85) were used to identify targets of gallincin in the Binding Database. After removing duplicate targets, the predicted targets of gallincin were obtained.

Retrieval of targets of disease
Therapeutic targets for colitis were retrieved from the Therapeutic Targets Database (http://bidd.nus.edu.sg/group/cjttd/) and
DrugBank (https://go.drugbank.com).\textsuperscript{18,19} The query keywords were “colitis” or “ulcerative colitis”. Results associated with infectious colitis were removed from the Therapeutic Targets Database and DrugBank results. Retrieved results from the two databases were merged, and non-repetitive targets were selected.

**Network construction and pathway analysis**

Targets of gallincin and colitis were used to construct an interaction network using Cytoscape software (https://cytoscape.org/, version 3.6.0). Pathway analysis was performed with the ClueGO/Clupedia applications within Cytoscape.\textsuperscript{20–22} “Homo sapiens” and “GO-Biological Process” were automatically selected. The \( p \)-value for statistical significance was kept at 0.01.

**Animals**

Male BALB/c mice (aged 6–8 weeks, weighing 18–23 g) were obtained from Tengxin Biotechnology (Chongqing, China). Mice were maintained in cages with fixed humidity (40\%) and environmental temperature (25°C) and a 12:12-hour dark:light cycle. Water and standard mouse food were provided ad libitum. Animal care and experiments were approved by the Ethical Institution of Guizhou Provincial People’s Hospital, Guizhou Medical University (No. 83, East Zhongshan Road, Guiyang 550002, Guizhou Province, China, date of approval: 17 March 2017).

**Animal model and drug intervention**

Experimental UC was generated by administration of 5\% dextran sulfate sodium (DSS; molecular weight 36–50 kDa; MP Biomedicals, Aurora, CO, USA) via an oral route in water for 7 days, followed by 1 day of normal drinking water. Seven days after the induction of colitis, all mice were randomly divided into four groups of eight animals each. Group 1, defined as the control group, was not administered DSS or gallincin; Group 2 was administered saline solution and 5\% DSS; Group 3 was administered 5\% DSS and low-dose gallincin (7 mg/kg, once daily; Sigma, St. Louis, MO, USA); Group 4, which served as the high-dose gallincin group, received 5\% DSS and high-dose gallincin (50 mg/kg, once daily). Drug dosage selection was based on preliminary experiments and the literature.\textsuperscript{23} Mice were sacrificed under inhalation anesthesia after 5 days of gallincin intervention.

**Assessment of colitis**

The disease activity index (DAI) was assessed according to the experimental approach reported by Murthy et al.\textsuperscript{24} Briefly, the DAI was determined by scoring changes in weight loss, stool occult blood or gross bleeding, and stool consistency. Hematoxylin and eosin staining was performed according to the conventional procedure used in our previous work.\textsuperscript{25} Assessment according to the histological scoring method reported by Ten Hove et al.\textsuperscript{26} was completed by two researchers in a double-blind manner. Histological scores were determined according to the degree of inflammation, depth of injury, regeneration, crypt injury, and extent of inflammation.

**Enzyme-linked immunosorbent assay (ELISA)**

Levels of TNF-\( \alpha \) and interleukin-1\( \beta \) (IL-1\( \beta \)) in homogenized colonic tissue were determined with ELISA kits according to the manufacturer’s instructions (Elabscience, Wuhan, China). D-lactate concentrations were also measured with an ELISA kit (Guangshui Biological Technology, Shanghai, China).
**Myeloperoxidase (MPO) activity**

Leucocyte MPO activity was assessed with a commercially available kit according to the manufacturer’s instructions (CytoStore, Alberta, Canada).

**Real-time quantitative PCR**

The primer sequences used were as follows: 27 TNF-α: 5′-TCTCTTCAAGGGACAAAGGCTG-3′, 5′-ATAG-CAAATCGGCTGACGGT-3′; IL-1β: 5′-TCGCTCAGG GTCAACAGAAA-3′, 5′-CCATCAGA GGCAAGGA-GGAA-3′. The PCR conditions were as follows: pre-denaturation at 95°C for 10 minutes, denaturation at 95°C for 15 s, and annealing-extension at 60°C for 1 minute, for a total of 40 cycles. The relative TNF-α and IL-1β mRNA levels were determined by the method reported in our previous study using the following formula: $2^{-\Delta\Delta Ct}$, where $\Delta\Delta Ct = (\Delta$ experimental mRNA$)-(\Delta$ control mRNA).25

**Immunohistochemistry**

Colonic specimens (3 μm thick) were successively treated with 10% formalin and paraffin. Next, sections were successively treated in series with ethanol (100%, 95%, 90%, 80%, and 70%), 1.5% hydrogen peroxide, and 3% bovine serum albumin. Then, sections were incubated with a zonula occludens 1 (ZO-1) antibody (1:500, Santa Cruz Biotechnology, Dallas, TX, USA), biotinylated secondary antibody (1:200, Dako, Glostrup, Denmark), diaminobenzidine tetrahydrochloride (Sigma), and 0.03% hydrogen peroxide. Negative controls underwent the same procedure but without the first antibody. Finally, the number of positive cells was evaluated by counting brown-stained cells in five random fields under a Leica microscope (Solms, Germany, 400×).

**Western blot analysis**

To examine protein expression in colonic tissue, extracts were prepared from colonic tissue, and occludin, ZO-1, and phosphorylated ERK1/2 (p-ERK1/2) levels in the intestinal tract were analyzed by western blot according to our previous study25 and standard methods28. The protein concentration was adjusted to 5 μg/μL. Protein samples were subjected to sodium dodecyl sulfate polyacrylamide gel electrophoresis and transferred to polyvinylidene fluoride membranes, which were then blocked with blocking buffer containing 10% skim milk. The membranes were then incubated with rabbit anti-mouse antibodies against occludin (1:100), ZO-1 (1:1000), p-ERK1/2 (1:100), and β-actin (1:150) (Santa Cruz Biotechnology). Next, the membranes were incubated with a biotin-labeled secondary antibody (goat anti-rabbit IgG, 1:2000, Beijing Zhongshan Jinqiao Company, China). The immune complexes were detected with an ECL system (Amersham Pharmacia Biotech Inc, Arlington, USA), and the bands were measured by a Fluorchem imaging system for quantitative densitometric analysis (Alpha Innotech Corp, San Leandro, CA, USA).

Figure 1. Chemical structure of gallincin.
Statistical method

All experimental data are presented as the mean ± standard deviation and were analyzed by analysis of variance or Student’s t-test. A value of \( p < 0.05 \) was considered statistically significant.

Results

Targets of gallincin or colitis

Approximately 146 predicted targets of gallincin (for the chemical structure, see Figure 1) were screened by the Swiss Target Prediction Database and Binding Database (Figure 2). A total of 121 targets of colitis were acquired from the Therapeutic Targets Database and DrugBank (Figure 3).

Collective targets of gallincin and colitis

Collective targets of gallincin and colitis are shown in Figure 4a and Figure 4b. Twelve mapping targets of colitis and gallincin were obtained (Figure 4a). The resulting protein interaction network, including 269 nodes and 267 edges, is shown in Figure 4b.

Figure 2. Gallincin-target interaction network.
Pathway analysis

The pathway analysis results are shown in Figure 5. Statistically significant pathways identified included “ammonium ion”, “immune”, and “regulation of synaptic transmission”, in addition to many other biological processes.

Regulation of inflammation by gallincin

Gallincin markedly alleviated DSS-induced colitis in mice ($p < 0.05$). Histological injury scores and the DAI are shown in Table 1. Nevertheless, there were no statistically significant differences between the low-dose and high-dose gallincin groups with regard to the DAI or histological injury scores.

Gallincin inhibited TNF-$\alpha$ and IL-1$\beta$ mRNA expression, MPO activity, and IL-1$\beta$ and TNF-$\alpha$ protein expression ($p < 0.05$). However, no significant differences were observed between the low-dose and high-dose gallincin groups. Data are shown in Table 1.

Effects of gallincin on intestinal barrier function

As shown in Table 1, concentrations of serum D-lactate, which is considered a
marker of increased intestinal permeability, were significantly reduced by gallincin ($p < 0.05$).

Tight junction (TJ) proteins, such as ZO-1 and occludin, are the main regulators of intestinal epithelial barrier function. In our experiment, the gallincin-treated groups exhibited significantly upregulated ZO-1 and occludin protein expression compared with the DSS group ($p < 0.05$, Figures 6–8).

**Figure 4.** Collective targets of gallincin and colitis. (a) Venn diagram of the collective targets. (b) Merged protein–protein interaction network for gallincin and colitis.

**Action pathway of gallincin**

Expression of p-ERK1/2 in the DSS group was significantly increased compared with the control group but was suppressed by gallincin, especially low-dose gallincin ($p < 0.05$, Figure 9).

**Discussion**

Our results demonstrated impaired barrier function in mice following DSS-induced colitis, as well as marked inhibition of inflammation by gallincin in vivo. Importantly, our findings indicate that gallincin restored colonic barrier function and ameliorated murine experimental colitis induced by DSS. The therapeutic effect of gallincin might be associated with
inhibition of TNF-α and IL-1β production and reduced leukocyte infiltration. These results suggest that gallincin could serve as an adjuvant or prophylactic agent to protect colorectal barrier function against mucosal inflammation. However, one limitation of this study was that examination of differences between the normal group and the gallincin group was not the goal of our experiments. Therefore, comprehensive experimental verification of these differences, including cell experiments and rescue experiments, will be necessary in future studies.

In our study, the UC model was successfully constructed, and impairment of intestinal barrier function was observed. In fact, this is not the first study to show colorectal barrier dysfunction in experimental colitis, as intestinal barrier damage has also been observed in other colitis models. Schmitz et al. reported that the inflamed
intestinal mucosa observed with UC exhibited impaired barrier function; altered TJ structures contributed to this barrier defect. Disruption of the TJ structure has been recognized as a potential cause or result of disease. In addition, genetic studies have indicated the importance of innate barrier function in the pathogenesis or etiology of IBD. These results support the potential of barrier-restoring agents to treat disease or prevent disease recurrence.

At present, the mechanism of impaired barrier function is unclear. Some articles have reported that proinflammatory factors, such as TNF-α and IL-1β, impair intestinal mucosal barrier function. However, increased colonic mucosal permeability increases the likelihood of antigen exposure to intestinal immune cells, which can trigger mucosal inflammation. These results suggest that inflammation and colonic barrier function are part of a complex regulatory network and can activate or inhibit one another by multiple modalities. Indeed, Poritz et al. reported that TJ changes can precede colitis, instead of being its consequence. Similarly, in the present study, we observed that serum concentrations of D-lactate, which was used as a marker for increased intestinal permeability, were increased at an early stage of DSS-induced colitis.

The intercellular TJ is the primary cellular determinant of the epithelial barricade. Dysregulation of TJ proteins is involved in the pathogenesis of UC. Occludin and ZO-1, which are two important epithelial TJ proteins, appear to be downregulated in UC and chronic pouchitis. Similarly, we observed remarkable decreases of ZO-1 and occludin expression in mice with DSS-induced colitis. Importantly, we also found that gallincin could maintain intestinal epithelial integrity by increasing ZO-1 and occludin

Table 1. Effects of gallincin on clinical indices, histological injury scores, cytokines, and D-lactate expression.

| Group          | Number | DAI | Histological scores | TNF-α mRNA | IL-1β mRNA | IL-1β mRNA | TNF-α (ng/L) | IL-1β (ng/L) | MPO activity (units/mg) | D-lactate (μg/mL) |
|----------------|--------|-----|---------------------|-------------|-------------|------------|--------------|--------------|-------------------------|------------------|
| Normal control | 8      | 0.43 ± 0.51 | 0.063 ± 0.011 | 0.034 ± 0.005 | 48.33 ± 4.43 | 24.62 ± 4.96 | 1.94 ± 0.23 | 1.46 ± 0.72 | 4.63 ± 0.44 | 1.26 ± 0.64 |
| DSS            | 8      | 1.04 ± 0.19 | 0.846 ± 0.14 | 0.0115 ± 0.02 | 195.05 ± 26.57 | 180.51 ± 0.43 | 16.67 ± 1.74 | 12.67 ± 1.42 | 12.67 ± 1.42 | 12.67 ± 1.42 |
| Low-dose gallincin | 8 | 0.41 ± 0.15 | 0.550 ± 0.54 | 0.0152 ± 0.068 | 80.50 ± 5.01 | 80.50 ± 5.01 | 14.38 ± 3.45 | 14.38 ± 3.45 | 14.38 ± 3.45 | 14.38 ± 3.45 |
| High-dose gallincin | 8 | 0.54 ± 0.16 | 5.63 ± 0.74 | 0.139 ± 0.074 | 0.156 ± 0.062 | 70.04 ± 10.90 | 77.46 ± 0.75 | 77.46 ± 0.75 | 77.46 ± 0.75 | 77.46 ± 0.75 |

Results are expressed as the mean ± SEM. *p < 0.05 (versus normal control group and gallincin group).

DAI, disease activity index; MPO, myeloperoxidase; DSS, dextran sulfate sodium; TNF, tumor necrosis factor; IL, interleukin.
expression, thereby diminishing the recurrence of or attenuating intestinal inflammation.

As described above, our results showed that gallincin inhibited inflammation and mucosal damage in mouse models. Anzoise et al.\textsuperscript{12} also observed that gallincin decreased levels of TNF-\textalpha, IL-6, and cyclooxygenase 2 in rats with experimental colitis. Another report from Chae et al.\textsuperscript{11} also
Figure 8. Effects of gallincin on occludin protein expression. (a) Western blot results display protein expression of occludin in the colonic tissues. (b) Densitometric analysis of occludin expression. Dextran sulfate sodium treatment reduced occludin expression, which was increased significantly with gallincin treatment. Data are expressed as $\bar{x}\pm S$ (each group, $n=8$). *$p<0.05$ (versus the control group, low-dose gallincin group, and high-dose gallincin group).

Figure 9. Effects of gallincin on phosphorylated extracellular-signal regulated protein kinase1/2 (p-ERK1/2) protein expression. (a) Western blot results display protein expression of p-ERK1/2 in colonic tissues. (b) Densitometric analysis of p-ERK1/2 expression. Dextran sulfate sodium treatment markedly increased p-ERK1/2 expression, which was decreased with gallincin treatment. Data are expressed as $\bar{x}\pm S$ (each group, $n=8$). *$p<0.05$ (versus the control group, low-dose gallincin group, and high-dose group).
showed that gallincin inhibited lipopolysaccharide-induced inflammatory cytokines by suppressing phosphorylation of ERK1/2. Based on these results, it is reasonable to expect that gallincin can protect the colonic barrier from damage, at least in part, via inhibition of excessive inflammation. In addition, mapping of target genes between drugs and diseases, including mitogen-activated protein kinase (MAPK), was identified with our network pharmacology method. Pathway analysis of target genes also indicated their involvement in the regulation of the inflammation and transmission processes. Subsequently, our animal experiment verified that gallincin inhibited ERK signaling, which is one of the best-characterized members of the MAPK family. There are similar reports of p-ERK1/2 inhibition by gallincin. Moreover, the involvement of ERK in colitis-associated T regulatory cell and Th17 cell development has been recognized. Therefore, it is possible that gallincin alleviates colitis at least in part by inhibiting ERK activation.

**Conclusion**

Based on network pharmacology analysis and experimental verification, gallincin may be a promising complementary or alternative therapeutic agent for UC. However, further studies are required to explore the long-term safety and exact mechanism of action of gallincin.

**Acknowledgements**

We thank the Chinese Medical Association and Takeda Science Foundation for providing scholarship support.

**Declaration of conflicting interest**

The authors declare that there is no conflict of interest.

**Funding**

This work was financially supported by the Cultivation Fund of the National Natural Science Foundation (Grant No. qiankehe2018-5764-11), Beijing Medical and Health Foundation (No. YWKJ1HKYXJ-B184053), and the Doctor Foundation of Guizhou Provincial People’s Hospital (No. GZSYBS (2017)09).

**ORCID iD**

De-jun Cui  https://orcid.org/0000-0002-3653-3058

**References**

1. Ungaro R, Mehandru S, Allen PB, et al. Ulcerative colitis. *Lancet* 2017; 389: 1756–1770. DOI: 10.1016/S0140-6736(16)32126-2.
2. Salim SY and Söderholm JD. Importance of disrupted intestinal barrier in inflammatory bowel diseases. *Inflamm Bowel Dis* 2011; 17: 362–381. DOI: 10.1002/ibd.21403.
3. Schoultz I and Keita ÅV. Cellular and molecular therapeutic targets in inflammatory bowel disease-focusing on intestinal barrier function. *Cells* 2019; 8: 193. DOI: 10.3390/cells8020193.
4. Bruewer M, Luegering A, Kucharzik T, et al. Proinflammatory cytokines disrupt epithelial barrier function by apoptosis-independent mechanisms. *J Immunol* 2003; 171: 6164–6172. DOI: 10.4049/jimmunol.171.11.6164.
5. Schmitz H, Fromm M, Bentzel CJ, et al. Tumor necrosis factor-alpha (TNFalpha) regulates the epithelial barrier in the human intestinal cell line HT-29/B6. *J Cell Sci* 1999; 112: 137–146.
6. Bressler B, Marshall JK, Bernstein CN, et al. Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: the Toronto consensus. *Gastroenterology* 2015; 148: 1035–1058.e3. DOI: 10.1053/j.gastro.2015.03.001.
7. Gilardi D, Fiorino G, Genua M, et al. Complementary and alternative medicine in inflammatory bowel diseases: what is the future in the field of herbal medicine?
8. Kornbluth A, Sachar DB and Practice Parameters Committee of the American College of Gastroenterology. Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2010; 105: 501–523; quiz 524. DOI: 10.1038/ajg.2009.727.

9. Triantafyllidi A, Xanthos T, Papalois A, et al. Herbal and plant therapy in patients with inflammatory bowel disease. Ann Gastroenterol 2015; 28: 210–220.

10. Lin Z, Wu H, Fu Y, et al. Application of herbaceous medications for inflammatory bowel disease as a complementary and alternative therapy. Inflamm Bowel Dis 2019; 25: 1886–1895. DOI: 10.1093/ibd/izz190.

11. Chae HS, Kang OH, Choi JG, et al. Methyl gallate inhibits the production of interleukin-6 and nitric oxide via down-regulation of extracellular-signal regulated protein kinase in RAW 264.7 cells. Am J Chin Med 2010; 38: 973–983. DOI: 10.1142/S0192415X10008391.

12. Anzoise ML, Basso AR, Del Mauro JS, et al. Potential usefulness of methyl gallate in the treatment of experimental colitis. Inflammopharmacology 2018; 26: 839–849. DOI: 10.1007/s10787-017-0412-6.

13. Bag PK, Roy N, Acharyya S, et al. In vivo fluid accumulation-inhibitory, anticolonization and anti-inflammatory and in vitro biofilm-inhibitory activities of methyl gallate isolated from Terminalia chebula against fluoroquinolones resistant Vibrio cholerae. Microb Pathog 2019; 128: 41–46. DOI: 10.1016/j.micpath.2018.12.037.

14. Zhu B, Zhang W, Lu Y, et al. Network pharmacology-based identification of protective mechanism of Panax notoginseng saponins on aspirin induced gastrointestinal injury. Biomed Pharmacother 2018; 105: 159–166. DOI: 10.1016/j.biopha.2018.04.054.

15. Zhou Z, Chen B, Chen S, et al. Applications of network pharmacology in traditional Chinese medicine research. Evid Based Complement Alternat Med 2020; 2020: 1646905. DOI: 10.1155/2020/1646905.

16. Grosdidier A, Zoete V and Michielin O. SwissDock, a protein-small molecule docking web service based on EADock DSS. Nucleic Acids Res 2011; 39: W270–W277. DOI: 10.1093/nar/gkr366.

17. Grosdidier A, Zoete V and Michielin O. Fast docking using the CHARMM force field with EADock DSS. J Comput Chem 2011; 32: 2149–2159. DOI: 10.1002/jcc.21797.

18. Wang Y, Zhang S, Li F, et al. Therapeutic Target Database 2020: enriched resource for facilitating research and early development of targeted therapeutics. Nucleic Acids Res 2020; 48: D1031–D1041. DOI: 10.1093/nar/gkz981.

19. Wishart DS, Feunang YD, Guo AC, et al. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res 2017; 46: D1074–D1082. DOI: 10.1093/nar/gkx1037.

20. Franz M, Lopes CT, Huck G, et al. Cytoscape.js: a graph theory library for visualisation and analysis. Bioinformatics 2016; 32: 309–311. DOI: 10.1093/bioinformatics/btv557.

21. Shannon P, Markiel A, Ozier O, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 2003; 13: 2498–2504. DOI: 10.1101/gr.1239303.

22. Bindea G, Galon J and Mlecnik B. CluePedia Cytoscape plugin: pathway insights using integrated experimental and in silico data. Bioinformatics 2013; 29: 661–663. DOI: 10.1093/bioinformatics/btt019.

23. Correa LB, Pádua TA, Seito LN, et al. Anti-inflammatory effect of methyl gallate on experimental arthritis: inhibition of neutrophil recruitment, production of inflammatory mediators, and activation of macrophages. J Nat Prod 2016; 79: 1554–1566. DOI: 10.1021/acs.jnatprod.5b01115.

24. Murthy SN, Cooper HS, Shim H, et al. Treatment of dextran sulfate sodium-induced murine colitis by intracolonic
cyclosporin. *Dig Dis Sci* 1993; 38: 1722–1734. DOI: 10.1007/bf01303184.

25. Zhang DK, He FQ, Li TK, et al. Glial-derived neurotrophic factor regulates intestinal epithelial barrier function and inflammation and is therapeutic for murine colitis. *J Pathol* 2010; 222: 213–222. DOI: 10.1002/path.2749.

26. Ten Hove T, Van Den Blink B, Pronk I, et al. Dichotomal role of inhibition of p38 MAPK with SB 203580 in experimental colitis. *Gut* 2002; 50: 507–512. DOI: 10.1136/gut.50.4.507.

27. Rioja I, Bush KA, Buckton JB, et al. Joint cytokine quantification in two rodent arthritis models: kinetics of expression, correlation of mRNA and protein levels and response to prednisolone treatment. *Clin Exp Immunol* 2004; 137: 65–73. DOI: 10.1111/j.1365-2249.2004.02499.x.

28. Sambrook J, Fritsch EF, Maniatis J, et al. *Molecular Cloning: A Laboratory Manual*. 2nd ed. New York: Cold Spring Harbor Laboratory Press, 1989, pp.1860–1863.

29. Poritz LS, Garver KI, Green C, et al. Loss of the tight junction protein ZO-1 in dextran sulfate sodium induced colitis. *J Surg Res* 2007; 140: 12–19. DOI: 10.1016/j.jss.2006.07.050.

30. Liberti A, Zucchetti I, Melillo D, et al. Chitin protects the gut epithelial barrier in a protochordate model of DSS-induced colitis. *Biol Open* 2018; 7: bio029355. DOI: 10.1242/bio.029355.

31. Tanideh N, Nematollahi SL, Hosseini SV, et al. The healing effect of *Hypericum perforatum* extract on acetic acid-induced ulcerative colitis in rat. *Ann Colorectal Res* 2014; 2: e25188. DOI: 10.17795/acr-25188.

32. Sepehrimanesh M, Samimi N, Koohi-Hosseinabadi O, et al. Effects of *Cupressus sempervirens* extract on the healing of acetic acid-induced ulcerative colitis in the rat. *J Coloproctol* 2018; 38: 309–313. DOI: 10.1016/j.jcrol.2018.07.002.

33. Schmitz H, Barmeyer C, Fromm M, et al. Altered tight junction structure contributes to the impaired epithelial barrier function in ulcerative colitis. *Gastroenterology* 1999; 116: 301–309. DOI: 10.1016/s0016-5085(99)70126-5.

34. Marchiando AM, Graham WV and Turner JR. Epithelial barriers in homeostasis and disease. *Annu Rev Pathol* 2010; 5: 119–144. DOI: 10.1146/annurev.pathol.4.110807.092135.

35. Landy J, Ronde E, English N, et al. Tight junctions in inflammatory bowel diseases and inflammatory bowel disease associated colorectal cancer. *World J Gastroenterol* 2016; 22: 3117–3126. DOI: 10.3748/wjg.v22.i11.3117.

36. Tan Y, Guan Y, Sun Y, et al. Correlation of intestinal mucosal healing and tight junction protein expression in ulcerative colitis patients. *Am J Med Sci* 2019; 357: 195–204. DOI: 10.1016/j.amjms.2018.11.011.

37. Liu H, Yao S, Dann SM, et al. ERK differentially regulates Th17- and Treg-cell development and contributes to the pathogenesis of colitis. *Eur J Immunol* 2013; 43: 1716–1726. DOI: 10.1002/eji.201242889.